Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTOIG8C9)

DOT Name Carboxypeptidase O (CPO)
Synonyms CPO; EC 3.4.17.-
Gene Name CPO
Related Disease
Alzheimer disease ( )
Cleft lip/palate ( )
DiGeorge syndrome ( )
Hereditary coproporphyria ( )
Melorheostosis ( )
Shprintzen-Goldberg syndrome ( )
UniProt ID
CBPO_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
5MRV
EC Number
3.4.17.-
Pfam ID
PF00246
Sequence
MKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWM
REISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQW
FVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGT
DLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQ
LILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARD
IGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSA
TMLLGLLVSCMSLL
Function
Carboxypeptidase which preferentially cleaves C-terminal acidic residues from peptides and proteins. Can also cleave C-terminal hydrophobic amino acids, with a preference for small residues over large residues.
Tissue Specificity Detected in enterocytes of the ileum.

Molecular Interaction Atlas (MIA) of This DOT

6 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Alzheimer disease DISF8S70 Strong Biomarker [1]
Cleft lip/palate DIS14IG3 Strong Biomarker [2]
DiGeorge syndrome DIST1RKO Strong Biomarker [3]
Hereditary coproporphyria DISDXYP2 Strong Genetic Variation [4]
Melorheostosis DISIMCL3 Strong Biomarker [5]
Shprintzen-Goldberg syndrome DISQH6P3 Strong Biomarker [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of Carboxypeptidase O (CPO). [6]
------------------------------------------------------------------------------------

References

1 Targeting Apolipoprotein E/Amyloid Binding by Peptoid CPO_A17-21P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline.Sci Rep. 2017 Aug 14;7(1):8009. doi: 10.1038/s41598-017-08604-8.
2 A comparison of DNA methylation in newborn blood samples from infants with and without orofacial clefts.Clin Epigenetics. 2019 Mar 4;11(1):40. doi: 10.1186/s13148-019-0638-9.
3 Prevalence of duplications and deletions of the 22q11 DiGeorge syndrome region in a population-based sample of infants with cleft palate.Am J Med Genet A. 2007 Jan 15;143A(2):129-34. doi: 10.1002/ajmg.a.31445.
4 Four novel mutations of the coproporphyrinogen III oxidase gene.Cell Mol Biol (Noisy-le-grand). 2009 Feb 16;55(1):15-8.
5 Involvement of the transcriptional factor GATA-1 in regulation of expression of coproporphyrinogen oxidase in mouse erythroleukemia cells.Biochem Biophys Res Commun. 1997 Apr 28;233(3):729-36. doi: 10.1006/bbrc.1997.6532.
6 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.